Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step

Biologicals

Volumn 40, Issue 6, 2012, Pages 473-481

  Koenderman, A H L ^a   ter Hart, H G J ^a   Prins de Nijs, I M M ^a   Bloem, J ^a   Stoffers, S ^a   Kempers, A ^a   Derksen, G J ^a   Al, B ^a   Dekker, L ^a   Over, J ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

Plasma derivatives; Virus removing filtration

Indexed keywords

BLOOD DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG SAFETY; FILTER; HEPATITIS A VIRUS; HUMAN PARVOVIRUS B19; NANOFILTRATION; NONHUMAN; PH; PRESSURE; PRIORITY JOURNAL; PROTEIN CONTENT; VIRUS TRANSMISSION;

BLOOD SUBSTITUTES; BLOOD-BORNE PATHOGENS; COMPLEMENT C1 INACTIVATOR PROTEINS; FILTRATION; IMMUNOGLOBULIN G; PROTHROMBIN; TRANSFERRIN; VIRUSES;

HEPATITIS A VIRUS; PARVOVIRUS; POLYGALA INCARNATA;

EID: 84868345483     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.07.010     Document Type: Article

References (24)

1. Burnouf T., Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000, 14:94-110.
2. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007, 101-117.
3. Chiavetta J.A., Escobar M., Newman A., He Y., Driezen P., Deeks S. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003, 169:767-773.
4. Pillonel J., Laperche S. Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of nucleic acid testing. Transfus Clin Biol 2004, 11:81-86.
5. Dwyre D.M., Fernando L.P., Holland P.V. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011, 100:92-98.
6. Hamamoto Y., Harada S., Kobayashi S., Yamaguchi K., Iijima H., Manabe S., et al. A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sang 1989, 56:230-236.
7. Burnouf-Radosevich M., Appourchaux P., Huart J.J., Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994, 67:132-138.
8. Troccoli N.M., McIver J., Losikoff A., Poiley J. Removal of viruses from human intravenous immune globulin by 35nm nanofiltration. Biologicals 1998, 26:321-329.
9. Burnouf T., Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003, 9:24-37.
10. Soluk L., Price H., Sinclair C., Atalla-Mikhail D., Genereux M. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview. Am J Ther 2008, 15:435-443.
11. Caballero S., Nieto S., Gajardo R., Jorquera J.I. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin. Biologicals 2010, 38(4):486-493.
12. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses; Revised (CPMB/BWP/268/95, London, 14 February 1996).
13. Note for guidance on plasma-derived medicinal products. CPMP/BWP/269/706271/2010 Committee for Proprietary Medicinal Products 2012, European Medicines Evaluation Agency.
14. Terpstra F.G., Kleijn M., Koenderman A.H.L., Over J., van Engelenburg F.A.C., Schuitemaker H., et al. Viral safety of C1-inhibitor NF. Biologicals 2007, 35:173-181.
15. ®, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006, 90:21-32.
16. ®), results of phase III and IV clinical studies. Haemophilia 2011, 17:439-445.
17. Yamaguchi K., Miyagawa E., Takahashi H., Miyazaki T., Ikeda H. Electron microscopic estimation of removal of parvovirus B19 (HPVB19) by nanofiltration with a novel filter membrane. J Memb Sci 2007, 298:99-109.
18. Von Bonsdorff L., Tölö H., Lindeberg E., Nyman T., Harju A., Parkkinen J. Development of a pharmaceutical apotransferrin product for iron binding therapy. Biologicals 2001, 29:27-237.
19. Roberts P.L., Feldman P., Crombie D., Walker C., Lowery K. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing conditions. Biologicals 2010, 38:303-310.
20. Menconi M.C., Maggi F., Zakrzewska K., Salotti V., Giovacchini P., Farina C., et al. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products. Transfus Med 2009, 19:213-217.
21. Yunoki M., Yamamoto S., Tanaka H., Nishigaki H., Tanaka Y., Nishida A., et al. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters. Vox Sang 2008, 95:94-100.
22. Hongo-Hirasaki T., Yamaguchi K., Yanagida K., Hayashida H., Ide S. Effects of varying virus-spiking conditions on a virus-removal filter Planova™ 20N in a virus validation study of antibody solutions. Biotechnol Prog 2011, 27(1):162-169.
23. Yunoki M., Tanaka H., Urayama T., Hattori S., Ohtani M., Ohkubo Y., et al. Prion removal by nanofiltration under different experimental conditions. Biologicals 2008, 36:27-36.
24. Yunoki M., Tanaka H., Urayama T., Kanai Y., Nishida A., Yoshikawa M., et al. Infectious prion protein in the filtrate even after 15 nm filtration. Biologicals 2010, 38(2):311-313.